z-logo
Premium
The Human Cancer Antigen Mesothelin Is More Efficiently Presented to the Mouse Immune System when Targeted to the DEC‐205/CD205 Receptor on Dendritic Cells
Author(s) -
Wang Bei,
Kuroiwa Janelle M.Y.,
He LiZhen,
Charalambous Anna,
Keler Tibor,
Steinman Ralph M.
Publication year - 2009
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2009.04933.x
Subject(s) - mesothelin , antigen , immune system , cancer research , epitope , antibody , cd8 , cytokine , immunology , t cell , biology
To develop a tumor vaccine directly targeting tumor antigen to dendritic cells in situ , we engineered human mesothelin (MSLN) into an antibody specific for mouse DEC‐205, a receptor for antigen presentation. We then characterized both T cell and humoral responses to human MSLN and compared immunizing efficacy of DEC‐205‐targeted MSLN to nontargeted protein after a single‐dose immunization. Targeting human MSLN to DEC‐205 receptor induced stronger CD4 + T‐cell responses compared to high doses of mesothelin protein. Approximately 0.5% CD4 + T cells were primed to produce IFN‐γ, tumor necrosis factor‐α, and IL‐2 via intracellular cytokine staining, and the T cells also could proliferate rapidly. The immune response exhibited breadth because the primed CD4 + T cells responded to at least three epitopes in the H‐2 b background. Targeting MSLN protein to DEC‐205 receptor also resulted in cross‐presentation to CD8 + T cells. Antibody responses against human MSLN were also detected in serum from primed mice by ELISA assays. In summary, targeting of MSLN to DEC‐205 improves the induction of CD4 + and CD8 + T‐cell immunity accompanied by an antibody response. DEC‐205‐targeting could be valuable for enhancing immunity to MSLN in cancers where this nonmutated protein is expressed.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here